Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6181 pages
Showing 3151 - 3200A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer
The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...
Addition of Adjuvant Palbociclib to Ongoing Endocrine Therapy in HR-Positive, HER2-Negative Early Breast Cancer: PALLAS Trial
As reported in The Lancet Oncology by Erica L. Mayer, MD, and colleagues, the second interim analysis of the phase III PALLAS trial showed no improvement in invasive disease–free survival with the addition of adjuvant palbociclib to ongoing endocrine therapy in patients with hormone receptor...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of the OlympiA trial, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival ...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer: What’s Next?
Because of their well-established efficacy, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are the standard of care in the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer. The question now is this: After disease progresses on a CDK4/6 inhibitor and endocrine...
John V. Cox, DO, MBA, on Reshaping Practice Models to Better Care for Patients With Cancer
John V. Cox, DO, MBA, of The University of Texas Southwestern Medical Center, summarizes his Joseph V. Simone Lecture, in which he stressed the need for coordinated care among practices. The concept of oncology medical homes, he says, has evolved to a broader-based model in which oncologists...
Study Examines Cost of Cancer Care in the United States in 2018
Care for the 15 most prevalent types of cancer in the United States cost approximately $156.2 billion for about 402,000 privately insured adult patients in 2018, according to a report published by Nicholas G. Zaorsky, MD, and colleagues in JAMA Network Open. The research team also found that...
Goal-Focused Emotion-Regulation Therapy for Young Adult Testicular Cancer Survivors
Psychological therapy may reduce adverse biobehavioral effects of testicular cancer in young adult survivors, according to a pilot study published by Hoyt et al in the American Journal of Men’s Health. Biobehavior is the interaction of biologic processes and behavior. The recently published...
Study Tracks Parental Hesitancy Trends Over the HPV Vaccine From 2010 to 2019
A study that tracked parental opinion about the human papillomavirus (HPV) vaccine showed that after hesitancy decreased for several years, hesitancy has now either stabilized or increased in some ethnic and age groups, according to results presented by Adjei Boakye et al at the 14th AACR...
The Wistar Institute Appoints Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement
The Wistar Institute has announced the appointment of Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Center. Dr. Tempera, who is also Associate Professor in the Gene Expression & Regulation Program, will lead the educational mission of ...
Michael Boyer, MBBS, FRACP, PhD, Honored With Adi F. Gazdar IASLC Merit Award
The International Association for the Study of Lung Cancer (IASLC) has named Michael Boyer, MBBS, FRACP, PhD, as the 2021 recipient of the Adi F. Gazdar IASLC Merit Award. The announcement was made during the IASLC 2021 World Conference on Lung Cancer. In 2019, the IASLC Board of Directors...
MSK Announces New Senior Vice President, Chief Nurse Executive, and Chair of Nursing
Memorial Sloan Kettering Cancer Center (MSK) has appointed Tracy Gosselin, PhD, RN, AOCN, NEA-BC, FAAN, as Senior Vice President, Chief Nurse Executive, and Chair of Nursing, effective November 2021. Dr. Gosselin currently serves as Chief Nursing & Patient Care Services Officer at Duke...
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer. Now, teams of researchers from these two leading centers are combining efforts after together ...
AACR Announces 2021 Distinguished Lectureship on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) has announced Graham A. Colditz, MD, DrPH, MPH, as the recipient of the 2021 AACR Distinguished Lectureship on the Science of Cancer Health Disparities. Dr. Colditz presented his award lecture, “Making Progress, Together: An Inclusive, Broad-Based ...
Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic
The resurging COVID-19 pandemic has reawakened challenges for patients and physicians—ones we all hoped were over—and presented stressful situations for patients and providers. Hospitals in some states, particularly those with lower vaccination rates, have faced levels of urgent illness that have...
Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients
Divya Gupta, MD, of the Stanford Cancer Center, discusses an intervention utilizing a computer model and lay care coaches to improve advance care planning conversations with patients who have metastatic cancer. The study, Dr. Gupta reports, showed a trend toward less intensive care for patients at...
FDA Pipeline: Recent Reviews, Designations, Applications, and Authorizations in the Oncology Space
Over the past month, the U.S. Food and Drug Administration (FDA) issued several regulatory decisions for novel treatments for patients with cancer. Priority Review for Relatlimab and Nivolumab Fixed-Dose Combination in Unresectable or Metastatic Melanoma The FDA accepted for Priority Review the...
Effect of Chronic Stress on Treatment Completion and Survival Outcomes in Patients With Breast Cancer
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node–positive or high-risk lymph node–negative HER2-negative breast cancer, according to results presented by Samilia Obeng-Gyasi, MD, MPH, at the 14th ...
ARAMIS Analysis: Darolutamide Shows Similar Benefits for Black Patients as Observed in the Overall Population
Black patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the phase III ARAMIS trial presented by Neal Shore, MD, at the 14th AACR...
Francis S. Collins, MD, PhD, to Step Down as Director of the National Institutes of Health
On October 5, Francis S. Collins, MD, PhD, announced his decision to end his tenure as Director of the National Institutes of Health (NIH) by the end of the year. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years....
Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide
Divya A. Parikh, MD, of Stanford University School of Medicine, discusses findings that suggest an evidence-based tool, the Serious Illness Conversation Guide, may engage patients with metastatic or recurrent urologic cancer in goals-of-care conversations, potentially resulting in an increase of...
How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care
Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...
Donations to St. Jude Children’s Research Center Soar; Inspiration4 SpaceX Journey Exceeds $200 Million Goal
On September 15, 2021, SpaceX launched the Inspiration4 mission, sending four civilians on a 3-day trip orbiting the earth. The passengers were the first to travel on an all-civilian space journey in an effort to further scientific and aerospace research while at the same time raise funds for...
FDA Recognizes Memorial Sloan Kettering Database of Molecular Tumor Marker Information
On October 7, the U.S. Food and Drug Administration (FDA) granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center Oncology Knowledge Base (OncoKB) as the first tumor mutation database to be included in the Public Human Genetic Variant Databases. The FDA recognized a...
President Biden Appoints Members to National Cancer Advisory Board
President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden...
Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence
Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...
Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology
Benjamin W. Corn, MD, of Shaare Zedek Medical Center in Jerusalem, discusses hope: what it takes for hope to thrive; how he and his colleagues are helping patients and providers become more hopeful through workshops; and his collaboration with the Southwest Oncology Group to aid patients, through...
Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring
Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial,...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL
On October 1, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ZUMA-3 Efficacy was evaluated ...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Improved Health Insurance Coverage, Access to Care May Lessen Racial/Ethnic Disparities in Childhood Cancer Survival
A new study published by Jingxuan Zhao, MPH, and colleagues in Cancer Epidemiology, Biomarkers & Prevention found racial/ethnic disparities in survival among newly diagnosed patients with childhood cancers in the United States, and that area-level socioeconomic status and health insurance...
Luis E. Aguirre, MD, on Chronic Myelomonocytic Leukemia: Keys to Assessment and Treatment
Luis E. Aguirre, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the subset of patients with chronic myelomonocytic leukemia who have a more indolent disease course. Features at diagnosis may include higher hemoglobin and platelet counts or JAK2, SF3B1, and IDH2 mutations; ...
Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma
Kieron M. Dunleavy, MD, of Georgetown University, offers insights into the latest data on treating patients with primary mediastinal B-cell lymphoma: the optimal regimen; whether radiotherapy or stem cell transplants are needed; new information on the biology of the disease; novel agents such as...
Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis...
Study Finds Genetic Predisposition to Higher Lymphocyte Production May Lead to Higher ALL Risk
Research published by Kachuri et al in the American Journal of Human Genetics reveals that children born with a genetic predisposition to produce more lymphocytes—particularly in relation to other types of white blood cells—may be at a higher risk of developing acute lymphoblastic leukemia (ALL)....
Sarah S. Mougalian, MD, on a Next-Day Access Program for Patients With Cancer
Sarah S. Mougalian, MD, of Yale Cancer Center, discusses the increasingly common problem of long wait times for access to oncology care. Her team developed a next-day access program in several of Yale’s oncology services, which was well received by patients and decreased the time to first visit.
Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery
Leticia Nogueira, PhD, MPH, of the American Cancer Society, discusses results from a study designed to evaluate the impact of Medicaid expansion under the Affordable Care Act (ACA). In Medicaid-expansion states, mortality among patients after lung cancer surgery decreased from 2.4% before the ACA...
FDA Expands Cetuximab Label With Combination of Encorafenib for Pretreated BRAF V600E Mutation–Positive Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has granted approval of a new indication for cetuximab (Erbitux) in combination with encorafenib (Braftovi) for the treatment of adult patients with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after prior...
Is MRI Cost-Effective for Detecting Cancer in Women With Very Dense Breasts?
A new paper published by Geuzinge et al in the Journal of the National Cancer Institute indicates that adding magnetic resonance imaging (MRI) scans to mammography is cost-effective for detecting breast cancer in women with very dense breasts. About 10% of women have extremely dense breasts, and...
Nasser K. Altorki, MD, on NSCLC: Adjuvant Atezolizumab for Stage IB–IIIA Disease
Nasser K. Altorki, MD, of Weill Medical College of Cornell University and NewYork-Presbyterian Hospital, discusses phase III data from the IMpower010 study, which showed that, compared with best supportive care, atezolizumab improved disease-free survival in patients with stage II–IIIA non–small...
Efficacy of Risk Calculator in Treating Elderly Patients With Cancer
Researchers have shown that using a validated risk calculator helped to drive informed treatment decisions in older patients with cancer. Mbewe et al identified the Cancer and Aging Research Group (CARG) calculator as a quick and helpful tool in assessing chemotherapy toxicity probability in...
Study Shows Benefits of a Next-Day Access Program for Patients With Cancer
A pilot program developed by researchers at Yale Cancer Center that offers patients next-day access for oncologic consultation showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report presented by Mougalian et al at the 2021 ASCO...
Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments
Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...
Manali I. Patel, MD, MPH, on Community-Based Intervention and Cancer Care Disparity
Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses data suggesting that community health workers and innovative payer models can better engage low-income and minority patients with cancer, improve their health-related quality of life, and reduce unwanted and unnecessary...
Tina Shih, PhD, on Trends in Total and Out-of-Pocket Costs of Cancer Care
Tina Shih, PhD, of The University of Texas MD Anderson Cancer Center, discusses the rising cost-sharing requirement from private insurance, which has worsened the financial burden for patients with cancer. She believes that cost-containment policies alone may not be enough to ease this hardship.
Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?
Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...
Active Living After Cancer Program May Improve Physical Functioning for Breast Cancer Survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, reported Tami-Maury et al in the journal Cancer. The results show the program could ...
New Study Aims to Measure Success of Phase III Oncology Trials
New research published by Shen et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival. The researchers analyzed 362 industry-sponsored phase...
UNMC Professor Emeritus James Edney, MD, Dies Tragically at 73
The University of Nebraska Medical Center (UNMC) in Omaha announced news of the death of James Edney, MD, Professor Emeritus in the Department of Surgery. Dr. Edney died on August 7 in a small plane crash in Minnesota. A Caring Physian and Educator UNMC Chancellor Jeffrey P. Gold, MD, said in a...
2021 Pan Pacific Lymphoma Conference Honors Outstanding Clinical Investigators
One of the biggest gatherings of clinicians and researchers practicing in the areas of lymphoma and transplantation, the 2021 Pan Pacific Lymphoma Conference took place August 9–13 in Hawaii. The conference, which was organized by the University of Nebraska Medical Center, offered participants an...
